The global cell separation technologies market, valued at USD 15.84 billion in 2024, is projected to reach USD 67.75 billion by 2034, growing at a CAGR of 15.64%. This growth is fueled by technological advancements, rising demand for immunotherapy and regenerative medicine, and increased research and development.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5352
Cell separation is the process of isolating specific cells from a mixed population. This technique is essential for molecular analysis, drug testing, disease modeling, and cell therapy research. It helps enhance the sensitivity of analytical models and allows for studying the effects of drugs on individual cell types. Traditional methods of cell separation include fluorescence-activated cell sorting (FACS), density gradient centrifugation, field flow fractionation (FFF), dielectrophoresis (DEP), magnet-activated cell sorting (MACS), pre-plating, and conditioned expansion media. Cells are typically isolated based on factors like size, density, shape, and surface protein expression.
The growing prevalence of chronic diseases and the limitations of small molecules in treating these conditions have led to the development of cell therapy products. Additionally, the increasing demand for stem cell therapies further drives the market. Technological advancements continue to lead to innovations in cell separation, while supportive government policies and rising investments in biotechnology also contribute to the growth of this market.
North America was the dominant region in the global cell separation technologies market in 2023. This growth is driven by continuous technological advancements, the presence of key industry players, and favorable government policies. For example, the California Institute for Regenerative Medicine (CIRM) recently approved $89 million in funding for stem cell and gene therapy research. In Canada, C3i Center Inc., a major player in cell and gene therapy contract manufacturing, has committed to investing $20 million annually for the next five years. These investments are aimed at creating large-scale facilities and ensuring Canada’s position in the growing cell and gene therapy market. Additionally, the Canadian government allocated $171.6 million to support five research organizations, including $48.5 million for the Stem Cell Network (SCN).
Asia-Pacific is expected to experience the fastest growth in the cell separation technologies market in the coming years. Factors such as a growing elderly population, rising rates of chronic diseases, increased investments, and ongoing research and development are key drivers. In China, the government is developing new laws and policies to support cellular therapies, with strategies tailored to its unique needs. Similarly, India is pushing for local production, as demonstrated by the unveiling of the country’s first home-grown gene therapy for cancer at IIT Bombay in 2024. Government initiatives like “Make in India” and “Atmanirbhar Bharat” are designed to promote affordable domestic production of cell therapy products.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/cell-separation-technologies-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5352
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The medical imaging market is witnessing rapid expansion worldwide, and Europe is emerging as a key contributor to this global… Read More
The global continuous glucose monitoring devices market size is calculated at USD 4.97 in 2024. Living with diabetes in Canada… Read More
The surgical sutures market in the United States is showing steady and promising growth, and here’s why! 👇 👵👴 An… Read More
Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More
Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More
Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data… Read More